interferon alfa + survivin-2B80-88

This is a combination immunotherapy consisting of interferon alfa (a cytokine with immunomodulatory and antitumor properties) and the HLA-A24-restricted peptide vaccine survivin-2B80–88. Survivin is a member of the inhibitor of apoptosis protein (IAP) family, highly expressed in many cancers but not in most normal tissues. The survivin-2B80–88 peptide is recognized by CD8+ cytotoxic T lymphocytes (CTLs), stimulating an immune response against tumor cells expressing this antigen. Interferon alfa acts as an immune adjuvant to enhance the efficacy of the vaccine by promoting CTL responses and modulating the tumor microenvironment. This combination has been evaluated in phase I clinical trials for metastatic urothelial cancer, colorectal cancer, pancreatic cancer, oral cancer, and other malignancies refractory to standard chemotherapy. Clinical studies have shown that this regimen can induce specific CTL responses with favorable safety profiles; some patients achieved stable disease or partial response[1][6][3].

Other names

interferon alpha + survivin-2B80-88IFNα + survivin 2B peptide vaccine